Literature DB >> 24668036

Smoking improves divided attention in schizophrenia.

Eike Ahlers1, Eric Hahn, Thi Minh Tam Ta, Elnaz Goudarzi, Michael Dettling, Andres H Neuhaus.   

Abstract

RATIONALE: Smoking is highly prevalent in schizophrenia, and there is evidence for beneficial effects on neurocognition. Smoking is therefore hypothesized a self-medication in schizophrenia. Although much effort is devoted to characterize those cognitive domains that potentially benefit from smoking, divided attention has not yet been investigated.
OBJECTIVES: The aim of this study was to analyze the interactional effects of diagnosis of schizophrenia and smoking history on divided attention.
METHODS: We investigated behavioral measures of divided attention in a sample of 48 schizophrenic patients and 48 controls (24 current smokers and non-smokers each) carefully matched for age, sex, education, verbal IQ, and smoking status with general linear models.
RESULTS: Most important within the scope of this study, significant interactions were found for valid reactions and errors of omission: Performance substantially increased in smoking schizophrenic patients, but not in controls. Further, these interactions were modified by sex, driven by female schizophrenic patients who showed a significant behavioral advantage of smokers over non-smokers, other than male schizophrenic patients or healthy controls who did not express this sex-specific pattern.
CONCLUSIONS: Results suggest a positive effect of smoking history on divided attention in schizophrenic patients. This study provides first evidence that the complex attention domain of divided attention is improved by smoking, which further substantiates the self-medication hypothesis of smoking in schizophrenia, although this has been shown mainly for sustained and selective attention. Gender-specific effects on cognition need to be further investigated.

Entities:  

Mesh:

Year:  2014        PMID: 24668036     DOI: 10.1007/s00213-014-3525-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  36 in total

1.  Smoking history and nicotine effects on cognitive performance.

Authors:  M Ernst; S J Heishman; L Spurgeon; E D London
Journal:  Neuropsychopharmacology       Date:  2001-09       Impact factor: 7.853

2.  Effects of smoking history on selective attention in schizophrenia.

Authors:  Constanze Hahn; Eric Hahn; Michael Dettling; Onur Güntürkün; Thi Minh Tam Ta; Andres H Neuhaus
Journal:  Neuropharmacology       Date:  2012-01-11       Impact factor: 5.250

3.  Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory.

Authors:  Susheel Vijayraghavan; Min Wang; Shari G Birnbaum; Graham V Williams; Amy F T Arnsten
Journal:  Nat Neurosci       Date:  2007-02-04       Impact factor: 24.884

4.  Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms.

Authors:  Kristi A Sacco; Angelo Termine; Aisha Seyal; Melissa M Dudas; Jennifer C Vessicchio; Suchitra Krishnan-Sarin; Peter I Jatlow; Bruce E Wexler; Tony P George
Journal:  Arch Gen Psychiatry       Date:  2005-06

Review 5.  A neurobiological basis for substance abuse comorbidity in schizophrenia.

Authors:  R A Chambers; J H Krystal; D W Self
Journal:  Biol Psychiatry       Date:  2001-07-15       Impact factor: 13.382

6.  Estrogen shapes dopamine-dependent cognitive processes: implications for women's health.

Authors:  Emily Jacobs; Mark D'Esposito
Journal:  J Neurosci       Date:  2011-04-06       Impact factor: 6.167

7.  Spatiotemporal mapping of sex differences during attentional processing.

Authors:  Andres H Neuhaus; Carolin Opgen-Rhein; Carsten Urbanek; Melanie Gross; Eric Hahn; Thi Minh Tam Ta; Simone Koehler; Michael Dettling
Journal:  Hum Brain Mapp       Date:  2009-09       Impact factor: 5.038

8.  Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs.

Authors:  Nancy C Andreasen; Marcus Pressler; Peg Nopoulos; Del Miller; Beng-Choon Ho
Journal:  Biol Psychiatry       Date:  2009-11-07       Impact factor: 13.382

9.  The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls.

Authors:  Ruth S Barr; Melissa A Culhane; Lindsay E Jubelt; Rana S Mufti; Michael A Dyer; Anthony P Weiss; Thilo Deckersbach; John F Kelly; Oliver Freudenreich; Donald C Goff; A Eden Evins
Journal:  Neuropsychopharmacology       Date:  2007-04-18       Impact factor: 7.853

10.  Estradiol modulates effort-based decision making in female rats.

Authors:  Kristina A Uban; Julia Rummel; Stan B Floresco; Liisa A M Galea
Journal:  Neuropsychopharmacology       Date:  2011-08-31       Impact factor: 7.853

View more
  7 in total

Review 1.  Smoking in schizophrenic patients: A critique of the self-medication hypothesis.

Authors:  Francesca Manzella; Susan E Maloney; George T Taylor
Journal:  World J Psychiatry       Date:  2015-03-22

Review 2.  Heritability of Neuropsychological Measures in Schizophrenia and Nonpsychiatric Populations: A Systematic Review and Meta-analysis.

Authors:  Gabriëlla A M Blokland; Raquelle I Mesholam-Gately; Timothea Toulopoulou; Elisabetta C Del Re; Max Lam; Lynn E DeLisi; Gary Donohoe; James T R Walters; Larry J Seidman; Tracey L Petryshen
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

3.  Cannabis use and cognitive function in first episode psychosis: differential effect of heavy use.

Authors:  Christian Núñez; Susana Ochoa; Elena Huerta-Ramos; Iris Baños; Ana Barajas; Montserrat Dolz; Bernardo Sánchez; Núria Del Cacho; Judith Usall
Journal:  Psychopharmacology (Berl)       Date:  2015-12-01       Impact factor: 4.530

4.  Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset.

Authors:  Romain Rey; Thierry D'Amato; Laurent Boyer; Lore Brunel; Bruno Aouizerate; Fabrice Berna; Delphine Capdevielle; Isabelle Chereau; Gabrielle Chesnoy-Servanin; Hélène Denizot; Jean-Michel Dorey; Caroline Dubertret; Julien Dubreucq; Catherine Faget; Franck Gabayet; Christophe Lancon; Jasmina Mallet; David Misdrahi; Christine Passerieux; Aurélie Schandrin; Franck Schürhoff; Mathieu Urbach; Pierre Vidailhet; Pierre-Michel Llorca; Guillaume Fond
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-04-07       Impact factor: 5.270

5.  California Verbal Learning Test-II performance in schizophrenia as a function of ascertainment strategy: comparing the first and second phases of the Consortium on the Genetics of Schizophrenia (COGS).

Authors:  William S Stone; Raquelle I Mesholam-Gately; David L Braff; Monica E Calkins; Robert Freedman; Michael F Green; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Gregory A Light; Keith H Nuechterlein; Ann Olincy; Allen D Radant; Larry J Siever; Jeremy M Silverman; Joyce Sprock; Catherine A Sugar; Neal R Swerdlow; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; Larry J Seidman
Journal:  Schizophr Res       Date:  2014-12-12       Impact factor: 4.939

Review 6.  Targeting Prefrontal Cortical Systems for Drug Development: Potential Therapies for Cognitive Disorders.

Authors:  Amy F T Arnsten; Min Wang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

7.  Unique Molecular Regulation of Higher-Order Prefrontal Cortical Circuits: Insights into the Neurobiology of Schizophrenia.

Authors:  Dibyadeep Datta; Amy F T Arnsten
Journal:  ACS Chem Neurosci       Date:  2018-03-01       Impact factor: 4.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.